4.24M
Категории: МедицинаМедицина ХимияХимия

Nucleic Acid Templated Chemistry (NATC) for the treatment of cancer

1.

Nucleic Acid Templated
Chemistry (NATC) for the
treatment of cancer
developed
by Cancevir AG
By Pavel Sergeev, PhD, email: [email protected]
Phone: +41 78 630 40 70
Non-confidential presentation

2.

Challenge
Source: WHO, International agency for research on cancer

3.

Vision of CANCEVIR AG
• We strive to develop an absolute new medical technology
against cancer diseases at metastatic stage
• We are dedicated to develop a highly specific and efficient
treatment to transform the perspective on approaches of
curing cancer
• Our goal is to have a cancer treatment without side effects
on the heart, liver and other organs of patients for every
type of cancer

4.

NATC technology selective tumor cell
killing
Inactive precursor of medication 1
linked to Oligonucleotide (stable)
Tumor cell
Inactive precursor of medication 2
linked to Oligonucleotide (stable)
tumor specific RNA
(mutated or overexpressed)
active drug is formed =>tumor killing
Tumor cell

5.

One example of NATC reaction
H N
CWIKRKRQQ
H
S
S
GIGAVLKVLTTGLPALI
C=O
S
3`-aaggtcggacccg
aatacgtccgacct-5
Recognition of cellular RNA
Chemical reaction within cells
H
N CWIKRKRQQ
H
GIGAVLKVLTTGLPALI
C=O
S
S
S
3`-aaggtcggacccgaatacgtccgacct-5`
5`-...cactgcattccagcctgggcttatgcaggctggagtgca...-3`
mRNA encoding BCR-ABL fusion protein

6.

After the nucleic acid
templated reaction
modified cytotoxin melittin is
released within
cancer cell from the
precursors.
GIGAVLKVLTTGLPALICWIKRKRQQ
S
S
3`-aaggtcggacccgaatacgtccgacct-5`
5`-...cactgcattccagcctgggcttatgcaggctggagtgca...-3`
mRNA encoding BCR-ABL fusion protein

7.

NATC technology offers many
advantages
• The active drug is only formed in tumor cells => specific killing
• Healthy cells are spared because they don’t have mutated RNA
• Somatic mutations leading to cancer are the target of medications
• Cancer of different origin can be targeted by the technology
• The NATC technology is able to recognize even the change of only
one nucleotide from 3 bln. nucleotides in Human genome

8.

Needed financing 2022 - 2026
Product
2022
Synthesis
CML
Employees
Financial need
2023
2024
2025
Preclinic / tox
6
12
10 M
10 M
2026
Phase I-III
27
35
40 M
35
60 M
Milestone
PoP in mammals
- File intellectual property
Milestone:
IND filing
Milestone:
PoC
Partnering opportunity
Exit I
Exit II
First round: CHF 20 M
Second round: CHF 100 M

9.

SWOT
Strengths:
In vivo PoP experiments exist
• Duration of the project is 5-7 years
Selective killing of tumor cells possible
Defined patient population
Highly differentiated from existing
medications
Opportunities:
Weaknesses:
Threats
Development of first-in-class molecules • Competition with other companies
Addressing unmet medical needs
Allows to treat different types of cancer
Generation of a pipeline in short time

10.

Thank you very much
for your attention
English     Русский Правила